Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 10/20 | 0.44 |
| ▸ | DRD3 | P35462 | 8/20 | 0.44 |
| ▸ | HTR2A | P28223 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143255 | 0.92 | DRD2 (0.47) | BDKRB1DRD2DRD3HTR2ALMNA | |
| SCHEMBL3149321 | 0.89 | KMT2A (0.47) | BDKRB1DRD2DRD3HTR2ALMNA | |
| SCHEMBL3148961 | 0.86 | DRD3 (0.46) | BDKRB1DRD2DRD3HTR2A | |
| SCHEMBL3157190 | 0.86 | CCR2 (0.52) | DRD2DRD3SMN1; SMN2ALDH1A1CCR2 | |
| SCHEMBL3149102 | 0.84 | DRD2 (0.51) | DRD2DRD3HTR2ALMNASMN1; SMN2 | |
| SCHEMBL3149168 | 0.84 | F10 (0.53) | DRD2DRD3SMN1; SMN2PSEN1PSEN2 | |
| SCHEMBL3143699 | 0.84 | DRD2 (0.47) | BDKRB1DRD2DRD3HTR2ALMNA | |
| SCHEMBL3148931 | 0.82 | CCR2 (0.56) | BDKRB1DRD2DRD3HTR2ACCR2 | |
| SCHEMBL3148934 | 0.82 | CCR2 (0.56) | BDKRB1DRD2DRD3HTR2ACCR2 | |
| SCHEMBL3157844 | 0.81 | DRD2 (0.47) | DRD2DRD3HTR2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | BDKRB1 1/4885DRD2 424/4885DRD3 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.